The ARS clinical CRO concluded a contract for a local registration Phase III open-label randomized comparative superiority clinical study of the efficacy and safety of a drug developed by an Indian pharmaceutical company in adult patients with acute bronchitis. 82 patients will be randomized into the clinical trial. Five Russian investigative centers will participate in the project. ARS will provide full-service support of the study as well as further marketing authorization of the medicine in Russia.